UK markets closed
NIKKEI 225
26,423.47 +269.66 (+1.03%) HANG SENG
21,853.07 +22.72 (+0.10%) CRUDE OIL
100.45 +0.95 (+0.95%) GOLD FUTURES
1,766.10 +2.20 (+0.12%) DOW
30,967.82 -129.44 (-0.42%) BTC-GBP
17,028.70 +330.59 (+1.98%)
Oxford BioMedica plc (OXB.L)
LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
At close: 04:35PM BST
| Previous close | 450.00 |
| Open | 455.00 |
| Bid | 454.00 x 0 |
| Ask | 456.50 x 0 |
| Day's range | 446.50 - 462.00 |
| 52-week range | 414.00 - 1,678.00 |
| Volume | |
| Avg. volume | 227,025 |
| Market cap | 436.18M |
| Beta (5Y monthly) | 0.93 |
| PE ratio (TTM) | 1,973.91 |
| EPS (TTM) | 0.23 |
| Earnings date | 20 Sept 2022 - 26 Sept 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1,341.17 |
- Simply Wall St.
Could The Market Be Wrong About Oxford Biomedica plc (LON:OXB) Given Its Attractive Financial Prospects?
Oxford Biomedica (LON:OXB) has had a rough three months with its share price down 35%. However, stock prices are...
- Globe Newswire
Oxford Biomedica Preliminary Results
Oxford Biomedica plcPreliminary results for the year ended 31 December 2021 Saving Lives Oxford, UK – 20 April 2022: Oxford Biomedica plc (LSE: OXB), (“Oxford Biomedica” or “the Group”), a leading cell and gene therapy group, today announces its preliminary results for the year ended 31 December 2021. Dr. Roch Doliveux, Chair and Interim Chief Executive Officer of Oxford Biomedica, said: “I am delighted with our performance in 2021 which was a true testament to the hard work of all our employees
- Yahoo Finance UK
Oxford Biomedica warns on sales after pausing AstraZeneca COVID vaccine
Investors dumped shares in the company on the back of the news, which sent it to the bottom of the FTSE 250.
© 2022 Yahoo. All rights reserved.
